Cargando…

The Potential Impact of Digital Biomarkers in Multiple Sclerosis in The Netherlands: An Early Health Technology Assessment of MS Sherpa

(1) Background: Monitoring of Multiple Sclerosis (MS) with eHealth interventions or digital biomarkers provides added value to the current care path. Evidence in the literature is currently scarce. MS sherpa is an eHealth intervention with digital biomarkers, aimed at monitoring symptom progression...

Descripción completa

Detalles Bibliográficos
Autores principales: Cloosterman, Sonja, Wijnands, Inez, Huygens, Simone, Wester, Valérie, Lam, Ka-Hoo, Strijbis, Eva, den Teuling, Bram, Versteegh, Matthijs
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534078/
https://www.ncbi.nlm.nih.gov/pubmed/34679370
http://dx.doi.org/10.3390/brainsci11101305
_version_ 1784587468374278144
author Cloosterman, Sonja
Wijnands, Inez
Huygens, Simone
Wester, Valérie
Lam, Ka-Hoo
Strijbis, Eva
den Teuling, Bram
Versteegh, Matthijs
author_facet Cloosterman, Sonja
Wijnands, Inez
Huygens, Simone
Wester, Valérie
Lam, Ka-Hoo
Strijbis, Eva
den Teuling, Bram
Versteegh, Matthijs
author_sort Cloosterman, Sonja
collection PubMed
description (1) Background: Monitoring of Multiple Sclerosis (MS) with eHealth interventions or digital biomarkers provides added value to the current care path. Evidence in the literature is currently scarce. MS sherpa is an eHealth intervention with digital biomarkers, aimed at monitoring symptom progression and disease activity. To show the added value of digital biomarker–based eHealth interventions to the MS care path, an early Health Technology Assessment (eHTA) was performed, with MS sherpa as an example, to assess the potential impact on treatment switches. (2) Methods: The eHTA was performed according to the Dutch guidelines for health economic evaluations. A decision analytic MS model was used to estimate the costs and benefits of MS standard care with and without use of MS sherpa, expressed in incremental cost-effectiveness ratios (ICERs) from both societal and health care perspectives. The efficacy of MS sherpa on early detection of active disease and the initiation of a treatment switch were modeled for a range of assumed efficacy (5%, 10%, 15%, 20%). (3) Results: From a societal perspective, for the efficacy of 15% or 20%, MS sherpa became dominant, which means cost-saving compared to the standard of care. MS sherpa is cost-effective in the 5% and 10% scenarios (ICERs EUR 14,535 and EUR 4069, respectively). From the health care perspective, all scenarios were cost-effective. Sensitivity analysis showed that increasing the efficacy of MS sherpa in detecting active disease early leading to treatment switches be the most impactful factor in the MS model. (4) Conclusions: The results indicate the potential of eHealth interventions to be cost-effective or even cost-saving in the MS care path. As such, digital biomarker–based eHealth interventions, like MS sherpa, are promising cost-effective solutions in optimizing MS disease management for people with MS, by detecting active disease early and helping neurologists in decisions on treatment switch.
format Online
Article
Text
id pubmed-8534078
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85340782021-10-23 The Potential Impact of Digital Biomarkers in Multiple Sclerosis in The Netherlands: An Early Health Technology Assessment of MS Sherpa Cloosterman, Sonja Wijnands, Inez Huygens, Simone Wester, Valérie Lam, Ka-Hoo Strijbis, Eva den Teuling, Bram Versteegh, Matthijs Brain Sci Article (1) Background: Monitoring of Multiple Sclerosis (MS) with eHealth interventions or digital biomarkers provides added value to the current care path. Evidence in the literature is currently scarce. MS sherpa is an eHealth intervention with digital biomarkers, aimed at monitoring symptom progression and disease activity. To show the added value of digital biomarker–based eHealth interventions to the MS care path, an early Health Technology Assessment (eHTA) was performed, with MS sherpa as an example, to assess the potential impact on treatment switches. (2) Methods: The eHTA was performed according to the Dutch guidelines for health economic evaluations. A decision analytic MS model was used to estimate the costs and benefits of MS standard care with and without use of MS sherpa, expressed in incremental cost-effectiveness ratios (ICERs) from both societal and health care perspectives. The efficacy of MS sherpa on early detection of active disease and the initiation of a treatment switch were modeled for a range of assumed efficacy (5%, 10%, 15%, 20%). (3) Results: From a societal perspective, for the efficacy of 15% or 20%, MS sherpa became dominant, which means cost-saving compared to the standard of care. MS sherpa is cost-effective in the 5% and 10% scenarios (ICERs EUR 14,535 and EUR 4069, respectively). From the health care perspective, all scenarios were cost-effective. Sensitivity analysis showed that increasing the efficacy of MS sherpa in detecting active disease early leading to treatment switches be the most impactful factor in the MS model. (4) Conclusions: The results indicate the potential of eHealth interventions to be cost-effective or even cost-saving in the MS care path. As such, digital biomarker–based eHealth interventions, like MS sherpa, are promising cost-effective solutions in optimizing MS disease management for people with MS, by detecting active disease early and helping neurologists in decisions on treatment switch. MDPI 2021-09-30 /pmc/articles/PMC8534078/ /pubmed/34679370 http://dx.doi.org/10.3390/brainsci11101305 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cloosterman, Sonja
Wijnands, Inez
Huygens, Simone
Wester, Valérie
Lam, Ka-Hoo
Strijbis, Eva
den Teuling, Bram
Versteegh, Matthijs
The Potential Impact of Digital Biomarkers in Multiple Sclerosis in The Netherlands: An Early Health Technology Assessment of MS Sherpa
title The Potential Impact of Digital Biomarkers in Multiple Sclerosis in The Netherlands: An Early Health Technology Assessment of MS Sherpa
title_full The Potential Impact of Digital Biomarkers in Multiple Sclerosis in The Netherlands: An Early Health Technology Assessment of MS Sherpa
title_fullStr The Potential Impact of Digital Biomarkers in Multiple Sclerosis in The Netherlands: An Early Health Technology Assessment of MS Sherpa
title_full_unstemmed The Potential Impact of Digital Biomarkers in Multiple Sclerosis in The Netherlands: An Early Health Technology Assessment of MS Sherpa
title_short The Potential Impact of Digital Biomarkers in Multiple Sclerosis in The Netherlands: An Early Health Technology Assessment of MS Sherpa
title_sort potential impact of digital biomarkers in multiple sclerosis in the netherlands: an early health technology assessment of ms sherpa
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534078/
https://www.ncbi.nlm.nih.gov/pubmed/34679370
http://dx.doi.org/10.3390/brainsci11101305
work_keys_str_mv AT cloostermansonja thepotentialimpactofdigitalbiomarkersinmultiplesclerosisinthenetherlandsanearlyhealthtechnologyassessmentofmssherpa
AT wijnandsinez thepotentialimpactofdigitalbiomarkersinmultiplesclerosisinthenetherlandsanearlyhealthtechnologyassessmentofmssherpa
AT huygenssimone thepotentialimpactofdigitalbiomarkersinmultiplesclerosisinthenetherlandsanearlyhealthtechnologyassessmentofmssherpa
AT westervalerie thepotentialimpactofdigitalbiomarkersinmultiplesclerosisinthenetherlandsanearlyhealthtechnologyassessmentofmssherpa
AT lamkahoo thepotentialimpactofdigitalbiomarkersinmultiplesclerosisinthenetherlandsanearlyhealthtechnologyassessmentofmssherpa
AT strijbiseva thepotentialimpactofdigitalbiomarkersinmultiplesclerosisinthenetherlandsanearlyhealthtechnologyassessmentofmssherpa
AT denteulingbram thepotentialimpactofdigitalbiomarkersinmultiplesclerosisinthenetherlandsanearlyhealthtechnologyassessmentofmssherpa
AT versteeghmatthijs thepotentialimpactofdigitalbiomarkersinmultiplesclerosisinthenetherlandsanearlyhealthtechnologyassessmentofmssherpa
AT cloostermansonja potentialimpactofdigitalbiomarkersinmultiplesclerosisinthenetherlandsanearlyhealthtechnologyassessmentofmssherpa
AT wijnandsinez potentialimpactofdigitalbiomarkersinmultiplesclerosisinthenetherlandsanearlyhealthtechnologyassessmentofmssherpa
AT huygenssimone potentialimpactofdigitalbiomarkersinmultiplesclerosisinthenetherlandsanearlyhealthtechnologyassessmentofmssherpa
AT westervalerie potentialimpactofdigitalbiomarkersinmultiplesclerosisinthenetherlandsanearlyhealthtechnologyassessmentofmssherpa
AT lamkahoo potentialimpactofdigitalbiomarkersinmultiplesclerosisinthenetherlandsanearlyhealthtechnologyassessmentofmssherpa
AT strijbiseva potentialimpactofdigitalbiomarkersinmultiplesclerosisinthenetherlandsanearlyhealthtechnologyassessmentofmssherpa
AT denteulingbram potentialimpactofdigitalbiomarkersinmultiplesclerosisinthenetherlandsanearlyhealthtechnologyassessmentofmssherpa
AT versteeghmatthijs potentialimpactofdigitalbiomarkersinmultiplesclerosisinthenetherlandsanearlyhealthtechnologyassessmentofmssherpa